Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.35 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23887008 | 0.98 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL30370507 | 0.98 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12401191 | 0.85 | ADRB1 (0.37) | KDM4ELMNAALDH1A1OXTRHSD17B10 | |
| SCHEMBL3872994 | 0.84 | PNMT (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12401182 | 0.81 | HTR2A (0.32) | OXTR | |
| SCHEMBL232442 | 0.74 | HTR2C (0.44) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL8410159 | 0.73 | DRD2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL17585073 | 0.69 | CD274 (0.43) | DRD2 | |
| Hydrochloric Acid SCHEMBL17583899 | 0.68 | CD274 (0.42) | — | |
| SCHEMBL11336504 | 0.68 | CYP2D6 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212528-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023078401-A1 | COMPOUNDS AS PROTEIN KINASE INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| EP-3153515-B1 | COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AB PHARMA LTD (CN) | 2020-08-12 | — | — | EP | disclosed |
| EP-2528922-B1 | POLYHETEROCYCLIC COMPOUNDS AS HCV INHIBITORS | AB PHARMA LTD (CN) | 2017-08-02 | — | — | EP | disclosed |
| EP-3153515-A1 | COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AB Pharma Ltd (CN) | 2017-04-12 | — | — | EP | disclosed |
| US-8815796-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-08-26 | — | — | US | disclosed |
| US-8815796-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-08-26 | — | — | US | disclosed |
| US-8653025-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-02-18 | — | — | US | disclosed |
| US-8653025-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-02-18 | — | — | US | disclosed |
| WO-2011091757-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-08-04 | — | — | WO | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | CHRNB2 4679/4885CHRNB4 4776/4885CHRNA3 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.